

Original Article

Cite this article: Hirayama T *et al.* (2024) Concomitant use of hydroxyzine and haloperidol did not worsen delirium in patients with cancer: A multicenter, retrospective, observational study. *Palliative and Supportive Care* 22(6), 1817–1824. <https://doi.org/10.1017/S1478951524000117>

Received: 4 April 2023

Revised: 10 October 2023

Accepted: 12 January 2024



Keywords:

Delirium; patient with cancer; haloperidol; hydroxyzine; concomitant use

Corresponding author: Hiromichi Matsuoka;

Email: hiromima@ncc.go.jp

Concomitant use of hydroxyzine and haloperidol did not worsen delirium in patients with cancer: A multicenter, retrospective, observational study

Takatoshi Hirayama, M.D.¹ , Emi Igarashi, M.D.², Saho Wada, M.D., PH.D.³, Ryoichi Sadahiro, M.D., PH.D.¹, Hanae Oshikiri, M.S.⁴, Masato Suzuka, M.S.⁴, Yuji Sato, PH.D.⁴, Yusuke Utsumi, M.S.^{2,5}, Atsushi Sakuma, M.D., PH.D.⁵, Rika Nakahara, M.D., PH.D.¹, Toru Imai, M.D.¹, Hiroaki Tomita, M.D., PH.D.^{2,5} and Hiromichi Matsuoka, M.D., PH.D.¹ 

¹Department of Psycho-Oncology, National Cancer Center Hospital, Tokyo, Japan; ²Department of Psychiatry, Tohoku University Graduate School of Medicine, Sendai, Japan; ³Division of Quality Assurance Programs, Institute for Cancer Control, National Cancer Center, Tokyo, Japan; ⁴Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan and ⁵Department of Psychiatry, Tohoku University Hospital, Sendai, Japan

Abstract

Objectives. There is concern that hydroxyzine exacerbates delirium, but a recent preliminary study suggested that the combination of haloperidol and hydroxyzine was effective against delirium. This study examined whether the concomitant use of hydroxyzine and haloperidol worsened delirium in patients with cancer.

Methods. This retrospective, observational study was conducted at 2 general hospitals in Japan. The medical records of patients with cancer who received haloperidol for delirium from July to December 2020 were reviewed. The treatments for delirium included haloperidol alone or haloperidol combined with hydroxyzine. The primary outcome was the duration from the first day of haloperidol administration to the resolution of delirium, defined as its absence for 2 consecutive days. The time to delirium resolution was analyzed to compare the haloperidol group and hydroxyzine combination group using the log-rank test with the Kaplan–Meier method. Secondary outcomes were (1) the total dose of antipsychotic medications, including those other than haloperidol (measured in chlorpromazine-equivalent doses), and (2) the frequencies of detrimental incidents during delirium, specifically falls and self-removal of drip infusion lines. The unpaired *t*-test and Fisher's exact test were used to analyze secondary outcomes.

Results. Of 497 patients who received haloperidol, 118 (23.7%) also received hydroxyzine. No significant difference in time to delirium resolution was found between the haloperidol group and the hydroxyzine combination group (log-rank test, $P = 0.631$). No significant difference between groups was found in either chlorpromazine-equivalent doses or the frequency of detrimental incidents.

Significance of results. This study showed that the concomitant use of hydroxyzine and haloperidol did not worsen delirium in patients with cancer.

Introduction

Delirium is a disorder of consciousness that develops acutely due to a variety of complex factors, including physical abnormalities, drug use, and environmental changes. It presents with symptoms of cognitive dysfunction such as disorientation, as well as various psychiatric symptoms such as hallucinations, delusions, and mood swings (American Psychiatric Association, DSM-5 Task Force 2013). Delirium is common in cancer treatment settings. It occurs in 10–31% of medical inpatients (Siddiqi *et al.* 2006), 37% of patients after surgery (Dyer *et al.* 1995), and 43% of patients with advanced cancer (Uchida *et al.* 2015), and the prevalence rises to 68% in terminal palliative care settings and to 88% in the 6 h before death (Lawlor *et al.* 2000). Delirium is a distressing experience for patients with cancer, caregivers, and healthcare providers (Breitbart *et al.* 2002a; Bruera *et al.* 2009), and it, therefore, must be carefully monitored and properly managed.

The management of delirium includes non-pharmacologic and pharmacologic therapies (Breitbart and Alici 2012). Pharmacotherapy primarily involves antipsychotic administration

© The Author(s), 2024. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

(Lawlor and Bush 2015). While haloperidol has been the standard treatment, atypical antipsychotics are often used instead of typical antipsychotics due to concerns that the latter increase the risk of death (Huybrechts *et al.* 2012). Among atypical antipsychotics, quetiapine, olanzapine, and risperidone have been commonly used to treat delirium (Breitbart *et al.* 2002b; Kishi *et al.* 2012; Tahir *et al.* 2010). It was also found, however, that higher doses of atypical antipsychotics were associated with increased mortality in patients with terminal cancer and delirium (Yokomichi *et al.* 2022). The lack of injectable formulations of atypical antipsychotics is a barrier to their application in patients with delirium who are unable to take them orally. Therefore, haloperidol remains a standard drug for delirium treatment.

However, the use of haloperidol increases the risk of symptom exacerbation in patients with comorbidities such as Parkinson's disease and Lewy body dementia, as well as in patients with unstable respiratory and cardiovascular conditions. A candidate alternative drug in such cases is hydroxyzine, a first-generation antihistamine used primarily for the treatment of itching, allergies, motion sickness-induced nausea, and insomnia and also widely prescribed for the symptomatic relief of anxiety and tension associated with psychoneurosis (Llorca *et al.* 2002). Hydroxyzine is also used clinically for sedation (Matsuda *et al.* 2020) and insomnia (Spahr *et al.* 2007) in patients who have difficulty using haloperidol or benzodiazepines due to Parkinson's disease or respiratory instability, respectively.

Mark Beers published the American Geriatrics Society (AGS) Beers Criteria[®] for Potentially Inappropriate Medication Use in Older Adults in 1991. The latest AGS Beers Criteria[®] updated in 2019 indicate that all first-generation antihistamines, including hydroxyzine, have potent anticholinergic properties and should not be used as hypnotics in older adults because of the risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity (AGS Beers Criteria[®] Update Expert Panel 2019). Nevertheless, regardless of this warning and similar ones discussed in review articles, hydroxyzine has been widely prescribed in treating delirium in the real world.

While there is widespread belief that hydroxyzine has potent anticholinergic properties, there is no evidence supporting this. Several *in vitro* studies evaluated the anticholinergic properties of hydroxyzine, and all found that hydroxyzine has low affinity for muscarinic receptors. Kubo *et al.* conducted radioligand binding assays using bovine cerebral cortex and found that while some H1-receptor antagonists (mequitazine, cyproheptadine, clemastine, diphenylpyraline, promethazine, homochlorcyclizine, and alimemazine) had high affinity for muscarinic receptors ($K_i = 5.0\text{--}38\text{ nM}$), others (mepyramine, terfenadine, methapyrilene, azelastine, meclizine, and hydroxyzine) had low affinity ($K_i = 3,600\text{--}30,000\text{ nM}$) (Kubo *et al.* 1987). Specifically, the K_i of hydroxyzine was $3,800 \pm 100\text{ nM}$. Later, a study conducted by Liu and Farley using mucus gland cells isolated from the airways of swine estimated that the K_i of hydroxyzine against muscarinic receptors was even higher, at $15,000\text{ nM}$ (Liu and Farley 2005). From a pharmacological standpoint, therefore, the recommendation of the Beers Criteria[®] to avoid hydroxyzine for delirium due to its potent anticholinergic properties is without merit.

Very few studies have investigated the efficacy of hydroxyzine in treating delirium, and the results have been controversial. For example, although a preliminary study reported that the combination of haloperidol and hydroxyzine effectively treated delirium (Sato and Tanaka 2022), it was a single-institution study that targeted only a small number of patients with a variety of diseases,

about half of which were cancers. Clinical guidelines for delirium in adult patients with cancer found no evidence that hydroxyzine was effective against delirium (Matsuda *et al.* 2020).

Considering the discrepancy between the Beers Criteria[®] recommendations and real-world findings, it is crucial to determine whether administering hydroxyzine to patients with cancer and delirium worsens their delirium. Therefore, we designed an observational, multicenter study to evaluate this issue.

We hypothesized that concomitantly administering hydroxyzine and haloperidol to patients with cancer and delirium would increase each of the following: (1) the number of days from the first day of haloperidol administration to the resolution of delirium; (2) the total dose of antipsychotic medications, including those other than haloperidol (measured in chlorpromazine-equivalent doses); and (3) the frequency of detrimental incidents during delirium, specifically falls and self-removal of drip infusion lines.

Methods

Subjects and interventions

The subjects of this retrospective observational study were patients with cancer who were admitted to the National Cancer Center Hospital (NCCH) and Tohoku University Hospital in Japan from July to December in 2020 and were treated for delirium with either haloperidol alone or the combination of haloperidol and hydroxyzine. Haloperidol (5-mg injection) and hydroxyzine (25-mg injection) were diluted in saline and administered intravenously over 30 min. Decisions to select and add medications were made by each patient's attending physician.

This study was approved by the NCCH Ethics Committee (approval number: 2021-197). The requirement for informed consent was waived due to the retrospective cohort design. Opt-out information was published on the NCCH website. This study was conducted in accordance with the principles of the Helsinki Declaration.

Survey items and evaluation procedures

Data on the following items were extracted from medical records by 2 psycho-oncologists: medical record number; age; sex; cancer diagnosis (in-hospital cancer registry); cancer treatment (surgery; chemotherapy, including cytotoxic agents, molecularly targeted drugs, and immune checkpoint inhibitors; radiation; hematopoietic stem cell transplantation; and follow-up); total hydroxyzine dose taken within 24 hours of the first dose of haloperidol; benzodiazepine use (daily use); number of days of delirium since the first day of haloperidol administration; detrimental incidents during delirium (falls and self-removal of drip infusion lines); total dose of antipsychotic medications during delirium, including those other than haloperidol (measured in chlorpromazine-equivalent doses); organic brain disorder (history of cerebral infarction or hemorrhage); and cognitive decline or dementia.

The diagnosis of delirium was determined based on the Nursing Delirium Screening Scale (Nu-DESC), a screening tool for delirium that nurses are expected to utilize in their daily care. The Nu-DESC includes 5 items, each rated on a scale from 0 to 2: disorientation, inappropriate behavior, inappropriate communication, illusions/hallucinations, and psychomotor retardation. The sensitivity and specificity of the scale for patients with cancer were 85.7% and 86.8%, respectively (Gaudreau *et al.* 2005). Delirium was defined by a Nu-DESC score of 1 point or higher (Jeong *et al.* 2020).

Nu-DESC was evaluated on a calendar-day basis (0:00–24:00), and if there were multiple scores of 0 and 1 or higher, a score of 1 or higher was used. For patients whose medical records contained an incomplete Nu-DESC score or none at all, 2 psycho-oncologists diagnosed delirium using other information in the medical records. A lack of information on delirium was assumed to indicate its absence.

The primary outcome was the number of days from the first day of haloperidol administration to the resolution of delirium. Delirium was considered to have resolved when it was absent for 2 consecutive days.

Secondary outcomes were (1) the total dose of antipsychotic medications, including those other than haloperidol (chlorpromazine-equivalent doses), and (2) the frequencies of detrimental incidents during delirium, specifically falls and self-removal of drip infusion lines.

Statistical analysis

Descriptive statistics were calculated for patient background, cause of delirium, and treatment used to resolve the cause of delirium. Cause of delirium was categorized by 2 psycho-oncologist reviewers using a Delirium Etiology checklist (Trzepacz et al. 2009). This tool categorizes potential causes into drug intoxication, drug withdrawal, metabolic/endocrine disturbance, traumatic brain injury, seizures, intracranial infections, systemic infection, intracranial neoplasm, systemic neoplasm, cerebrovascular, organ insufficiency, other central nervous system, and other. The other category included etiologies such as heat stroke, hypothermia, radiation, postoperative state, immunosuppressed, and fractures. If there was more than 1 cause of delirium, the 2 psycho-oncologists decided on 1 direct cause after discussion. The treatment for the direct cause of delirium was chosen as the treatment used to resolve the cause of delirium. Fisher’s exact test and the unpaired *t*-test were performed to compare demographic information between patients with and without hydroxyzine use. Fisher’s exact test was performed to compare cause of delirium and treatment used to resolve the cause of delirium between patients with and without hydroxyzine use. Time to delirium resolution (the primary outcome) was compared between the haloperidol group and the hydroxyzine combination group using the log-rank test with the Kaplan–Meier method. Multivariable Cox regression analysis was performed for the associations between extracted data items and the mean number of days from the first day of haloperidol administration to the resolution of delirium, both with and without hydroxyzine use. Regarding secondary outcomes, the unpaired *t*-test was used to analyze the association between the presence or absence of hydroxyzine use and antipsychotic dosage; a 2-sided *P* value < 0.05 was considered significant. In addition, Fisher’s exact test was used to compare the association between the presence or absence of hydroxyzine use and the frequencies of detrimental incidents during delirium; a *P* value < 0.05 was considered significant. Analyses were conducted using IBM SPSS Statistics version 27 (IBM Corp., Armonk, NY, USA). There were no missing data.

Results

Patient background

Patient background data are shown in Table 1. From July to December 2020, 497 patients received haloperidol for the treatment of delirium. Of these, 379 (76.3%) received haloperidol

Table 1. Patient background

	All (n = 497)	Haloperidol group (n = 379)	Hydroxyzine combination group (n = 118)	<i>P</i> value
Age (years), mean (SD)*	67.4 (13.1)	64.8 (14.2)	68.3 (12.6)	0.018
Sex, n (%)*				0.003
Male	293 (59.0)	238 (62.8)	55 (46.6)	
Female	204 (41.0)	141 (37.2)	63 (53.4)	
Cancer type, n (%) (primary site)				
Digestive system	212 (42.8)	161 (42.5)	51 (43.3)	0.915
Lung*	93 (18.7)	83 (21.9)	10 (8.5)	0.001
Head and neck	44 (8.9)	33 (8.7)	11 (9.3)	0.853
Urogenital system	35 (7.0)	28 (7.4)	7 (5.9)	0.684
Gynecological system	32 (6.4)	25 (6.6)	7 (5.9)	1.000
Hematological*	27 (5.4)	13 (3.4)	14 (11.9)	0.002
Breast	16 (3.2)	11 (2.9)	5 (4.2)	0.549
Brain	11 (2.2)	9 (2.4)	2 (1.7)	1.000
Skin	9 (1.8)	5 (1.3)	4 (3.4)	0.226
Bone/soft tissue	8 (1.6)	5 (1.3)	3 (2.5)	0.402
Others	10 (2.0)	6 (1.6)	4 (3.4)	0.258
Treatment, n (%)				
Surgery*				0.043
Yes	209 (42.1)	169 (44.6)	40 (33.9)	
No	288 (57.9)	210 (55.4)	78 (66.1)	
Chemotherapy ^a				0.707
Yes	112 (22.5)	84 (22.2)	28 (23.7)	
No	385 (77.5)	295 (77.8)	90 (76.3)	
Radiation				1.000
Yes	93 (18.7)	71 (18.7)	22 (18.6)	
No	404 (81.3)	308 (81.3)	96 (81.4)	
Hematopoietic stem cell transplantation				0.142
Yes	11 (2.2)	6 (1.6)	5 (4.2)	
No	486 (97.8)	373 (98.4)	113 (95.8)	
Follow-up				0.329
Yes	122 (24.5)	89 (23.5)	33 (28.0)	
No	375 (75.5)	290 (76.5)	85 (72.0)	
Use of benzodiazepines (daily use), n (%)				0.508
Yes	56 (11.3)	45 (11.9)	11 (9.3)	

(Continued)

Table 1. (Continued.)

	All (n = 497)	Haloperidol group (n = 379)	Hydroxyzine combination group (n = 118)	P value
No	441 (88.7)	334 (88.1)	107 (90.7)	
Organic brain disorder (history of cerebral infarction or hemorrhage), n (%)				0.867
Yes	55 (11.1)	43 (11.4)	12 (10.2)	
No	442 (88.9)	336 (88.6)	106 (89.8)	
Cognitive decline or dementia, n (%)				0.218
Yes	35 (7.0)	30 (7.9)	5 (4.2)	
No	462 (93.0)	349 (92.1)	113 (95.8)	

^aIncluding cytotoxic agents, molecularly targeted drugs, and immune checkpoint inhibitors.
* $P < 0.05$.

without hydroxyzine and 118 (23.7%) received the combination of haloperidol and hydroxyzine. The patients' mean age (standard deviation) was 67.4 years (13.1). The cancer types (defined by primary site) included digestive system cancer ($n = 212$; 42.8%), lung cancer ($n = 93$; 18.7%), head and neck cancer ($n = 44$; 8.9%), urogenital system cancer ($n = 35$; 7.0%), gynecological system cancer ($n = 32$; 6.4%), hematological cancer ($n = 27$; 5.4%), and others ($n = 54$; 10.9%). The most common treatment was surgery ($n = 209$, 42.1%). Lung cancer ($P = 0.001$) and surgery ($P = 0.043$) were significantly more common in the haloperidol group than in the hydroxyzine combination group. In contrast, the hydroxyzine combination group was characterized by a significantly higher mean age ($P = 0.018$) and significantly higher numbers of women ($P = 0.003$) and patients with hematological cancer ($P = 0.002$).

The causes of delirium are shown in Table 2. Systemic infection was more common in the hydroxyzine combination group than in the haloperidol group. Postoperative state was more common in the haloperidol group than in the hydroxyzine combination group.

The treatment used to resolve the cause of delirium is shown in Table 3. Symptomatic therapy was more common in the haloperidol group than in the hydroxyzine combination group. Antibiotic treatment was more common in the hydroxyzine combination group than in the haloperidol group.

Primary outcome

Figure 1 shows the Kaplan–Meier estimates for the number of days from the first day of haloperidol administration to the resolution of delirium. No significant difference in time to delirium resolution was found between the haloperidol group and the hydroxyzine combination group (log-rank test, $P = 0.631$). After the absence of multicollinearity was confirmed, multivariate analysis was conducted. This showed that surgery was significantly associated with a smaller number of days to delirium resolution ($P = 0.005$, hazard ratio: 0.472, 95% confidence interval: 0.279–0.800) (Table 4).

Table 2. Causes of delirium

	All (n = 497)	Haloperidol group (n = 379)	Hydroxyzine combination group (n = 118)	P value
Causes of delirium, n (%)				0.003
Systemic neoplasm	129 (26.0)	100 (26.4)	29 (24.6)	
Systemic infection ^a	56 (11.3)	31 (8.2)	25 (21.2)	
Metabolic/endocrine disturbance ^b	23 (4.6)	18 (4.7)	5 (4.2)	
Drug intoxication ^c	11 (2.2)	9 (2.4)	2 (1.7)	
Intracranial neoplasm ^d	9 (1.8)	5 (1.3)	4 (3.4)	
Intracranial infection	6 (1.2)	5 (1.3)	1 (0.8)	
Organ insufficiency (cardiac and hepatic)	5 (1.0)	4 (1.1)	1 (0.8)	
Cerebrovascular (cerebral infarction)	2 (0.4)	0 (0.0)	2 (1.7)	
Other (postoperative state)	166 (33.4)	135 (35.6)	31 (26.3)	
Unknown	90 (18.1)	72 (19.0)	18 (15.3)	

^aIncluding bacteremia, sepsis, respiratory, pyelonephritis, and cellulitis.

^bIncluding volume depletion, hypoxia, anemia, hypercalcemia, hyponatremia, and hyperammonemia.

^cIncluding sedative – hypnotic and prescribed drug (opioid, steroid, and benzodiazepines).

^dIncluding metastasis and meningeal carcinomatosis.

Secondary outcomes

As measured in chlorpromazine-equivalent doses, there was no significant difference in the total dose of antipsychotic medications between the haloperidol group and the hydroxyzine combination group (Table 5). There were also no significant differences between the 2 groups regarding the frequencies of falls and self-removal of drip infusion lines during delirium (Table 6).

Discussion

This observational study is the first to show that the concomitant use of hydroxyzine and haloperidol did not worsen delirium among patients with cancer. No significant difference in the time to delirium resolution was found between the haloperidol group and the hydroxyzine combination group. The 2 groups also did not differ in terms of the total dose of antipsychotic medications (in chlorpromazine-equivalent doses) or the frequencies of detrimental incidents during delirium, specifically falls and self-removal of drip infusion lines.

Hydroxyzine is a first-generation antihistamine that permeates the blood–brain barrier. It inhibits the action of histamine in the thalamus, hypothalamus, and limbic system and has anxiolytic and sedative effects (Sato and Tanaka 2022). The tuberomammillary nucleus, located in the posterior hypothalamus, is the only source

Table 3. Treatment used to resolve the cause of delirium

Treatment used to resolve the cause of delirium, n (%)	All (n = 497)	Haloperidol group (n = 379)	Hydroxyzine combination group (n = 118)	P value
	Symptomatic therapy	329 (66.2)	255 (67.3)	
Antibiotic treatment	46 (9.3)	23 (6.1)	23 (19.5)	
Blood transfusion	10 (2.0)	10 (2.6)	0 (0.0)	
Reduction or discontinuation of drug	10 (2.0)	8 (2.1)	2 (1.7)	
Electrolyte correction	8 (1.6)	5 (1.3)	3 (2.5)	
Steroid	7 (1.4)	6 (1.6)	1 (0.8)	
Drainage	2 (0.4)	2 (0.5)	0 (0.0)	
Amino acid preparations	2 (0.4)	1 (0.3)	1 (0.8)	
Hydration	1 (0.2)	1 (0.3)	0 (0.0)	
Radiation	1 (0.2)	1 (0.3)	0 (0.0)	
Diuretic	1 (0.2)	1 (0.3)	0 (0.0)	
Unknown	80 (16.1)	66 (17.4)	14 (11.9)	

of histamine pathways in the human brain and is considered to be an arousal center. Many antihistamines, including hydroxyzine, are H1 blockers that are sedating and are, therefore, sometimes used for insomnia (Abad and Guillemineault 2018) and as alternatives to benzodiazepines for anxiety and panic attacks in both inpatient and outpatient settings (Guaiana et al. 2010). Antihistamines are generally well tolerated, aside from adverse effects like dry mouth,

constipation, sedation, and risks of use while driving (Garakani et al. 2020).

Though H1-receptor antagonists have been reported to be associated with the risk of delirium (AGS Beers Criteria® Update Expert Panel 2019), this issue was only examined prospectively for diphenhydramine, and no significantly increased risk of delirium was found (Clegg and Young 2011). Thus, there is little evidence that hydroxyzine increases the risk of developing delirium. Furthermore, the Ki value of hydroxyzine for muscarinic receptors in the bovine cerebral cortex was $3,800 \pm 100$ nM, suggesting a lower affinity and therefore a weaker anticholinergic effect than other first-generation antihistamines (Kubo et al. 1987). On the other hand, hydroxyzine also has dopamine D2 antagonist activity (Haraguchi et al. 1997). It may, therefore, have a positive impact on delirium because the psychiatric and behavioral disturbances seen in delirium are associated with the direct excitatory effects of excess dopamine, including glutamate-mediated neuropathy (Graham 1984) and apoptosis (Pedrosa and Soares-da-Silva 2002). Also, since most antipsychotic drugs have strong dopamine D2 antagonist activity and have been reported to be useful for the treatment of delirium (Boettger et al. 2011), hydroxyzine may also be effective.

The use of antipsychotics in patients with delirium has been shown to induce dose-dependent sedation, extrapyramidal symptoms, and QT prolongation syndrome (Kishi et al. 2016), all of which can lead to increased mortality in older adults and patients with dementia (Gill et al. 2007; Schneeweiss et al. 2007). QT is the time from the beginning of the Q wave to the end of the T wave on the electrocardiogram. It is the time from the beginning to the end of ventricular excitement. Delirium with agitation that causes psychomotor activation results in violent behavior and other incidents, such as falls and self-removal of drip infusion lines, that burden nursing care (Devlin et al. 2018). Therefore, developing drug therapies to treat delirium with few side effects is an important clinical challenge.

In clinical practice, if the effect of haloperidol is insufficient, additional doses of haloperidol may be given or benzodiazepines may be administered concomitantly. However, overdoses of haloperidol may cause aspiration, drug-induced parkinsonism, and cardiotoxicity. In addition, the concomitant use of




Figure 1. The Kaplan–Meier estimates for number of days from the first day of haloperidol administration to resolution of delirium.

Table 4. Multivariate analysis of the number of days from the first day of haloperidol administration to delirium resolution

	Hazard ratio	95% confidence interval	P value
Medicine			
Haloperidol group	1.00 (Reference)		
Hydroxyzine combination	0.75	0.50–1.12	0.159
Mean age, years (SD)	1.00	0.98–1.01	0.651
Sex			
Male	1.00 (Reference)		
Female	0.99	0.68–1.45	0.963
Cancer type (primary site)			
Digestive system	0.87	0.56–1.35	0.535
Lung	1.00 (Reference)		
Head and neck	1.76	0.99–3.13	0.054
Urogenital system	0.70	0.32–1.53	0.370
Gynecological system	1.32	0.59–2.98	0.500
Hematological	0.45	0.20–1.03	0.058
Breast	1.91	0.82–4.46	0.136
Brain	0.50	0.15–1.63	0.249
Skin	0.91	0.33–2.47	0.851
Bone/soft tissue	1.19	0.44–3.23	0.738
Others	1.60	0.54–4.75	0.397
Treatment			
Surgery*			
Yes	0.47	0.28–0.80	0.005
No	1.00 (Reference)		
Chemotherapy^a			
Yes	0.89	0.54–1.46	0.642
No	1.00 (Reference)		
Radiation			
Yes	0.66	0.39–1.09	0.102
No	1.00 (Reference)		
Hematopoietic stem cell transplantation			
Yes	1.09	0.22–5.50	0.914

(Continued)

Table 4. (Continued.)

	Hazard ratio	95% confidence interval	P value
No	1.00 (Reference)		
Follow-up			
Yes	0.87	0.52–1.46	0.605
No	1.00 (Reference)		
Use of benzodiazepines (daily use)			
Yes	1.14	0.76–1.71	0.529
No	1.00 (Reference)		
Organic brain disorder (history of cerebral infarction or hemorrhage)			
Yes	0.65	0.41–1.04	0.076
No	1.00 (Reference)		
Cognitive decline or dementia			
Yes	0.71	0.40–1.26	0.243
No	1.00 (Reference)		

^aIncluding cytotoxic agents, molecularly targeted drugs, and immune checkpoint inhibitors. **P* < 0.05.

Table 5. Dosage of any antipsychotic medications including those other than haloperidol (chlorpromazine-equivalent doses)

	All (<i>n</i> = 497)	Haloperidol group (<i>n</i> = 379)	Hydroxyzine combination group (<i>n</i> = 118)	<i>t</i>	<i>P</i> value
Dose (mg), mean (SD)	585.9 (1,390)	594.4 (1,511.2)	558.7 (900.8)	-0.243	0.808

benzodiazepines may cause respiratory depression. In 1 study, for example, flunitrazepam-induced respiratory depression was reported in 17% of patients with terminal illness (Matsuo and Morita 2007). In addition, patients with delirium and cancer pain are more likely to use opioid analgesics, and the concomitant use of opioids and benzodiazepines increases the risk of excessive respiratory depression (Baillargeon et al. 2019). These limitations may be avoided by treating delirium with the combination of haloperidol and hydroxyzine.

A strength of this study is that it included approximately 500 patients with cancer at multiple facilities. Though a previous study compared a haloperidol group and a hydroxyzine combination group, it included only 39 people, including patients without cancer, at 1 facility (Sato and Tanaka 2022). That study

Table 6. Detrimental incidents, specifically falls and self-removal of drip infusion lines, during delirium

	All (n = 497)	Haloperidol group (n = 379)	Hydroxyzine combination group (n = 118)	<i>p</i> value
Detrimental incidents during delirium, n (%)				0.234
Yes	26 (5.2)	17 (4.5)	9 (7.6)	
Falls	8 (30.8)	5 (29.4)	3 (33.3)	
Self-removal of drip infusion line	18 (69.2)	12 (70.6)	6 (66.7)	
No	471 (94.8)	362 (95.5)	109 (92.4)	

suggested that haloperidol plus hydroxyzine was effective against delirium, including in patients without cancer. These findings were consistent with our own, which demonstrated that the concomitant use of hydroxyzine and haloperidol in patients with cancer did not exacerbate delirium or increase the frequency of incidents such as falls and self-removal of drip infusion lines when compared to haloperidol alone.

The limitations of this study were as follows. First, the study used a retrospective, observational design. Our findings suggested that the concomitant use of hydroxyzine and haloperidol did not worsen delirium in patients with cancer, but the effectiveness of hydroxyzine against delirium was unclear. The chlorpromazine-equivalent dose was lower in the hydroxyzine combination group than in the haloperidol group; while the difference was not statistically significant, it suggests that hydroxyzine may not adversely affect delirium. To evaluate the benefit of hydroxyzine in patients with cancer, a prospective study is needed. Second, the choice of haloperidol alone or in combination with hydroxyzine was determined by each patient's physician. The evaluation of medical records in this study showed that many prescriptions were written by physicians who were not specialized in psychiatry, and there was uncertainty about the reasons for their drug selection. Third, although the diagnosis of delirium was determined based on the Nu-DESC, the validity and reliability of the Japanese version have not been confirmed. Fourth, some aspects of the patients' backgrounds were not equivalent between the haloperidol group and the hydroxyzine combination group. In particular, the hydroxyzine combination group was characterized by a higher mean age and a lower incidence of surgery. Older age has been shown to be the most significant risk factor for delirium (Inouye et al. 2014), while postoperative delirium usually resolves within a week (Lee et al. 2018). Our analysis also showed that postoperatively, the duration from the first day of haloperidol administration to the resolution of delirium was brief. Therefore, older age and fewer surgeries in the hydroxyzine combination group would be expected to prolong delirium in this group, and the fact that the duration of delirium in this group did not differ significantly from that in the haloperidol group supported the non-inferiority of the concomitant use of hydroxyzine and haloperidol compared with haloperidol alone against delirium. Finally, some aspects of the causes of delirium were not equivalent between the haloperidol group and the hydroxyzine combination group. Systemic infection was more common in the hydroxyzine combination group than in

the haloperidol group. Because some infection in delirious patients with cancer was reported to be associated with non-reversibility, more systemic infection in the hydroxyzine combination group would be expected to prolong delirium in this group. Postoperative state was more common in the haloperidol group than in the hydroxyzine combination group. Because postoperative delirium usually resolves within a week (Lee et al. 2018), fewer postoperative state in the hydroxyzine combination group would be expected to prolong delirium in this group. Therefore, these supported the non-inferiority of the concomitant use of hydroxyzine and haloperidol compared with haloperidol alone against delirium.

Despite these limitations, our findings suggest that treating delirium with the combination of hydroxyzine and haloperidol did not worsen delirium in patients with cancer, indicating that hydroxyzine itself does not exacerbate delirium in this population. Thus, due to hydroxyzine's inherent effects on anxiety and tension, it is expected to be effective for these symptoms in patients with delirium.

Conclusion

This study showed that the concomitant use of hydroxyzine and haloperidol did not worsen delirium in patients with cancer. As a next step, we aim to conduct a prospective study to evaluate the effectiveness of hydroxyzine for delirium in patients with cancer.

Acknowledgments. The authors express their gratitude to Tomoko Mizuta (Department of Psycho-Oncology, National Cancer Center Hospital, Japan), Masamitsu Maekawa (Department of Pharmaceutical Sciences, Tohoku University Hospital and Faculty of Pharmaceutical Sciences, Tohoku University, Japan) and Tatsuro Ishikawa (Department of Medical Information Technology Center, Tohoku University Hospital, Japan).

Author contributions. All authors contributed to the study conception and design. Data preparation and analysis were performed by Takatoshi Hirayama, Saho Wada, Ryoichi Sadahiro, and Hiromichi Matsuoka. Data collection was performed by Takatoshi Hirayama, Emi Igarashi, Hanae Oshikiri, Masato Suzuka, Yuji Sato, and Toru Imai. The first draft of the manuscript was written by Takatoshi Hirayama, Emi Igarashi, Saho Wada, Ryoichi Sadahiro, Hanae Oshikiri, Masato Suzuka, Yuji Sato, Yusuke Utsumi, Atsushi Sakuma, Rika Nakahara, Toru Imai, Hiroaki Tomita, and Hiromichi Matsuoka commented on subsequent versions of the manuscript. All authors read and approved the final manuscript.

Funding. This research received no specific grant from any funding agency in the commercial or not-for-profit sector.

Competing interests. The authors have no relevant financial or non-financial interests to disclose.

Ethical approval. This study was performed in line with the principles of the Helsinki Declaration. Approval was granted by the National Cancer Center Institutional Review Board on September 22, 2021 (approval number, 2021-197).

References

- Abad VC and Guilleminault C (2018) Insomnia in elderly patients: Recommendations for pharmacological management. *Drugs Aging* 35(9), 791–817. doi:10.1007/s40266-018-0569-8
- American Geriatrics Society Beers Criteria® Update Expert Panel (2019) American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. *Journal of the American Geriatrics Society* 67(4), 674–694. doi:10.1111/jgs.15767

- American Psychiatric Association, DSM-5 Task Force** (2013) *Diagnostic and Statistical Manual of Mental Disorders: DSM-5™*, 5th edn. Washington, DC: American Psychiatric Publishing, Inc.
- Baillargeon J, Singh G, Kuo YF, et al.** (2019) Association of opioid and benzodiazepine use with adverse respiratory events in older adults with chronic obstructive pulmonary disease. *Annals of the American Thoracic Society* **16**(10), 1245–1251. doi:10.1513/AnnalsATS.201901-024OC
- Boettger S, Friedlander M, Breitbart W, et al.** (2011) Aripiprazole and haloperidol in the treatment of delirium. *Australian & New Zealand Journal of Psychiatry* **45**(6), 477–482. doi:10.3109/00048674.2011.543411
- Breitbart W and Alici Y** (2012) Evidence-based treatment of delirium in patients with cancer. *Journal of Clinical Oncology ASCO* **30**(11), 1206–1214. doi:10.1200/JCO.2011.39.8784
- Breitbart W, Gibson C and Tremblay A** (2002a) The delirium experience: Delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses. *Psychosomatics* **43**(3), 183–194. doi:10.1176/appi.psy.43.3.183
- Breitbart W, Tremblay A and Gibson C** (2002b) An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. *Psychosomatics* **43**(3), 175–182. doi:10.1176/appi.psy.43.3.175
- Bruera E, Bush SH, Willey J, et al.** (2009) Impact of delirium and recall on the level of distress in patients with advanced cancer and their family caregivers. *Cancer* **115**(9), 2004–2012. doi:10.1002/cncr.24215
- Clegg A and Young JB** (2011) Which medications to avoid in people at risk of delirium: A systematic review. *Age Ageing* **40**(1), 23–29. doi:10.1093/ageing/afq140
- Devlin JW, Skrobik Y, Gélinas C, et al.** (2018) Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. *Critical Care Medicine* **46**(9), e825–e873. doi:10.1097/CCM.00000000000003299
- Dyer CB, Ashton CM and Teasdale TA** (1995) Postoperative delirium. A review of 80 primary data-collection studies. *Archives of Internal Medicine* **155**(5), 461–465. doi:10.1001/archinte.155.5.461
- Garakani A, Murrough JW, Freire RC, et al.** (2020) Pharmacotherapy of anxiety disorders: Current and emerging treatment options. *Frontiers in Psychiatry* **11**, 595584. doi:10.3389/fpsy.2020.595584
- Gaudreau JD, Gagnon P, Harel F, et al.** (2005) Fast, systematic, and continuous delirium assessment in hospitalized patients: The nursing delirium screening scale. *Journal of Pain Symptom Management* **29**(4), 368–375. doi:10.1016/j.jpainsymman.2004.07.009
- Gill SS, Bronskill SE, Norman SL, et al.** (2007) Antipsychotic drug use and mortality in older adults with dementia. *Annals of Internal Medicine* **146**(11), 775–786. doi:10.7326/0003-4819-146-11-200706050-00006
- Graham DG** (1984) Catecholamine toxicity: A proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. *Neurotoxicology* **5**, 83–95.
- Guaiana G, Barbui C and Cipriani A** (2010) Hydroxyzine for generalised anxiety disorder. *Cochrane Database of Systematic Reviews* (12), CD006815. doi:10.1002/14651858.CD006815.pub2
- Haraguchi K, Ito K, Kotaki H, et al.** (1997) Prediction of drug-induced catalepsy based on dopamine D1, D2, and muscarinic acetylcholine receptor occupancies. *Drug Metabolism and Disposition* **25**(6), 675–684.
- Huybrechts KE, Gerhard T, Crystal S, et al.** (2012) Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: Population based cohort study. *BMJ* **344**, e977. doi:10.1136/bmj.e977
- Inouye SK, Westendorp RG and Saczynski JS** (2014) Delirium in elderly people. *The Lancet* **383**(9920), 911–922. doi:10.1016/S0140-6736(13)60688-1
- Jeong E, Park J and Lee J** (2020) Diagnostic test accuracy of the Nursing Delirium Screening Scale: A systematic review and meta-analysis. *Journal of Advanced Nursing* **76**(10), 2510–2521. doi:10.1111/jan.14482
- Kishi T, Hirota T, Matsunaga S, et al.** (2016) Antipsychotic medications for the treatment of delirium: A systematic review and meta-analysis of randomised controlled trials. *Journal of Neurology, Neurosurgery, and Psychiatry* **87**(7), 767–774. doi:10.1136/jnnp-2015-311049
- Kishi Y, Kato M, Okuyama T, et al.** (2012) Treatment of delirium with risperidone in cancer patients. *Psychiatry and Clinical Neurosciences* **66**(5), 411–417. doi:10.1111/j.1440-1819.2012.02346.x
- Kubo N, Shirakawa O, Kuno T, et al.** (1987) Antimuscarinic effects of antihistamines: Quantitative evaluation by receptor-binding assay. *The Japanese Journal of Pharmacology* **43**(3), 277–282. doi:10.1254/jjp.43.277
- Lawlor PG and Bush SH** (2015) Delirium in patients with cancer: Assessment, impact, mechanisms and management. *Nature Reviews Clinical Oncology* **12**(2), 77–92. doi:10.1038/nrclinonc.2014.147
- Lawlor PG, Gagnon B, Mancini IL, et al.** (2000) Occurrence, causes, and outcome of delirium in patients with advanced cancer: A prospective study. *Archives of Internal Medicine* **160**(6), 786–794. doi:10.1001/archinte.160.6.786
- Lee H, Ju JW, Oh SY, et al.** (2018) Impact of timing and duration of postoperative delirium: A retrospective observational study. *Surgery* **164**(1), 137–143. doi:10.1016/j.surg.2018.02.001
- Liu H and Farley JM** (2005) Effects of first and second generation antihistamines on muscarinic induced mucus gland cell ion transport. *BMC Pharmacology* **5**, 8. doi:10.1186/1471-2210-5-8
- Llorca PM, Spadone C, Sol O, et al.** (2002) Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: A 3-month double-blind study. *The Journal of Clinical Psychiatry* **63**(11), 1020–1027. doi:10.4088/jcp.v63n1112
- Matsuda Y, Tanimukai H, Inoue S, et al.** (2020) JPOS/JASCC clinical guidelines for delirium in adult cancer patients: A summary of recommendation statements. *Japanese Journal of Clinical Oncology* **50**(5), 586–593. doi:10.1093/jjco/hyaa003
- Matsuo N and Morita T** (2007) Efficacy, safety, and cost effectiveness of intravenous midazolam and flunitrazepam for primary insomnia in terminally ill patients with cancer: A retrospective multicenter audit study. *Journal of Palliative Medicine* **10**(5), 1054–1062. doi:10.1089/jpm.2007.0016
- Pedrosa R and Soares-da-Silva P** (2002) Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine. *British Journal of Pharmacology* **137**(8), 1305–1313. doi:10.1038/sj.bjp.0704982
- Sato J and Tanaka R** (2022) A retrospective comparison of haloperidol and hydroxyzine combination therapy with haloperidol alone in the treatment of overactive delirium. *Supportive Care in Cancer* **30**(6), 4889–4896. doi:10.1007/s00520-022-06903-z
- Schneeweiss S, Setoguchi S, Brookhart A, et al.** (2007) Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. *CMAJ* **176**(5), 627–632. doi:10.1503/cmaj.061250
- Siddiqi N, House AO and Holmes JD** (2006) Occurrence and outcome of delirium in medical in-patients: A systematic literature review. *Age Ageing* **35**(4), 350–364. doi:10.1093/ageing/af005
- Spahr L, Coeytaux A, Giostra E, et al.** (2007) Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: A randomized controlled pilot trial. *The American Journal of Gastroenterology* **102**(4), 744–753. doi:10.1111/j.1572-0241.2006.01028.x
- Tahir TA, Eeles E, Karapareddy V, et al.** (2010) A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. *Journal of Psychosomatic Research* **69**(5), 485–490. doi:10.1016/j.jpsychores.2010.05.006
- Trzepacz PT, Maldonado JR, Kean J, et al.** (2009). The Delirium Rating Scale Revised-98 (DRS-R98) administration manual. A guide to increase understanding of how to solicit delirium symptoms to administer the DRS-R98. Indianapolis, IN: Trzepacz.
- Uchida M, Okuyama T, Ito Y, et al.** (2015) Prevalence, course and factors associated with delirium in elderly patients with advanced cancer: A longitudinal observational study. *Japanese Journal of Clinical Oncology* **45**(10), 934–940. doi:10.1093/jjco/hyv100
- Yokomichi N, Maeda I, Morita T, et al.** (2022) Association of antipsychotic dose with survival of advanced cancer patients with delirium. *Journal of Pain Symptom Management* **64**(1), 28–36. doi:10.1016/j.jpainsymman.2022.03.005